Glioblastoma — clinical trials in Germany
21 open options
- EXPANDED ACCESSAVAILABLE
Glioblastoma and Individualized Therapies
Vaccination — 1 site
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1RECRUITING
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
NK-92/5.28.z · Ezabenlimab — 5 sites
- TRIALNARECRUITING
Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial
Oncomagnetic device — 6 sites
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
- TRIALEARLY_PHASE1RECRUITING
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Larotrectinib · Larotrectinib surgical — 21 sites
- TRIALNARECRUITING
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Radiofrequency electromagnetic field treatment — 1 site
- TRIALNARECRUITING
Glioblastoma Radiotherapy Using IMRT or Proton Beams
Proton irradiation · Photon irradiation — 3 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2RECRUITING
Surgery for Recurrent Glioblastoma
Surgery followed by adjuvant second-line therapy · Second-line therapy alone — 25 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALPHASE3RECRUITING
Anterior Temporal Lobectomy in Temporal Glioblastoma
Anterior temporal lobectomy (ATL) · Gross Total Resection (GTR) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Gliolan · Radiodynamic therapy — 1 site
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- TRIALPHASE2RECRUITING
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Dose escalation of radiation dose beyond the therapeutic standard — 9 sites
- TRIALEARLY_PHASE1RECRUITING
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Lorlatinib · Lorlatinib with chemotherapy1 · Lorlatinib with chemotherapy 2 — 18 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
- TRIALPHASE2RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ribociclib · Everolimus · Temozolomide (TMZ) — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.